The detailed information for PTAB case with proceeding number IPR2025-00947 filed by AZURITY PHARMACEUTICALS, INC. against Helsinn Healthcare S.A. on May 1, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-00947
Filing Date
May 1, 2025
Petitioner
AZURITY PHARMACEUTICALS, INC.
Respondent
Helsinn Healthcare S.A.
Status
Pending
Respondent Application Number
14069927
Respondent Tech Center
1600
Respondent Patent Number
9186357

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Notice: Notice filing date accorded

Jun 4, 2025PAPERBOARD

Power of Attorney for Patent Owner Helsinn Healthcare S.A.

May 22, 2025PAPERPATENT OWNER

Patent Owner's Mandatory Notices

May 22, 2025PAPERPATENT OWNER

US8623826 to F. Trento et al.

May 1, 2025EXHIBITPETITIONER

US9186357 to F. Trento et al.

May 1, 2025EXHIBITPETITIONER

US9943515 to F. Trento et al.

May 1, 2025EXHIBITPETITIONER

US10828297 to F. Trento et al.

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 13/077,462 - Part 1

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 13/077,462 - Part 2

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 14/069,927

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 15/003,327 - Part 1

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 15/003,327 - Part 2

May 1, 2025EXHIBITPETITIONER

Prosecution history for U.S. Appl. 15/923,050

May 1, 2025EXHIBITPETITIONER

J. Herrstedt & P. Dombernowsky, Anti-Emetic Therapy in Cancer Chemotherapy:

May 1, 2025EXHIBITPETITIONER

T. Hoffmann et al., Design and synthesis of a novel, achiral class of highl

May 1, 2025EXHIBITPETITIONER

R. Hargreaves, Imaging Substance P Receptors (NK1) in the Living Human Brai

May 1, 2025EXHIBITPETITIONER

The Antiemetic Subcommittee of the Multinational Association of Supportive

May 1, 2025EXHIBITPETITIONER

M. Bös et al., 4-phenyl-pyridine derivatives, U.S. Patent 6,297,375 B1 (iss

May 1, 2025EXHIBITPETITIONER

Eisai, Inc., ALOXI (palonosetron HCl) Capsules, package insert (Aug. 2008)

May 1, 2025EXHIBITPETITIONER

J.D. Herrington et al., Randomized, Placebo-controlled, Pilot Study Evaluat

May 1, 2025EXHIBITPETITIONER

D. Bonadeo et al., WO 2008/04955 - Soft Capsules Comprising Palonosetron Hy

May 1, 2025EXHIBITPETITIONER

R.J. Gralla et al., Recommendations for the use of antiemetics: evidence-ba

May 1, 2025EXHIBITPETITIONER

K. Jordan et al., Guidelines for Antiemetic Treatment of Chemotherapy-Induc

May 1, 2025EXHIBITPETITIONER

Curriculum Vitae of Dr. Stephen J. Peroutka

May 1, 2025EXHIBITPETITIONER

G.K. Reddy et al., Novel Neurokinin-1 Antagonists as Antiemetics for the Tr

May 1, 2025EXHIBITPETITIONER

M.S. Aapro et al., A phase III, double-blind, randomized trial of palonoset

May 1, 2025EXHIBITPETITIONER

D. Campos et al., Prevention of cisplatin-induced emesis by the oral neurok

May 1, 2025EXHIBITPETITIONER

A.E. Chang et al., eds., Oncology: An Evidence-Based Approach (2006)

May 1, 2025EXHIBITPETITIONER

S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist Aprepi

May 1, 2025EXHIBITPETITIONER

S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist Aprepi

May 1, 2025EXHIBITPETITIONER

A. De Leon, Palonosetron (Aloxi): a second-generation 5-HT3 receptor antago

May 1, 2025EXHIBITPETITIONER

R.A. Duffy, Potential therapeutic targets for neurokinin-1 receptor antagon

May 1, 2025EXHIBITPETITIONER

Press Release, Eisai Co., FDA Approves ALOXIⓇ (Palonosetron HCl) Capsules

May 1, 2025EXHIBITPETITIONER

Merck & Co., EMEND, package insert (2008)

May 1, 2025EXHIBITPETITIONER

DailyMed, EMEND (aprepitant) Capsule, https://web.archive.org/web/200902021

May 1, 2025EXHIBITPETITIONER

U.S. Food and Drug Administration, General Considerations for the Clinical

May 1, 2025EXHIBITPETITIONER

U.S. Food and Drug Administration, Q3A Impurities in New Drug Substances (2

May 1, 2025EXHIBITPETITIONER

D.G. Warr et al., Efficacy and tolerability of aprepitant for the preventio

May 1, 2025EXHIBITPETITIONER

S.M. Grunberg et al., Effectiveness of a single-day three-drug regimen of d

May 1, 2025EXHIBITPETITIONER

Press Release, GSK provides update on regulatory filings for Zunrisa/Rezoni

May 1, 2025EXHIBITPETITIONER

P.J. Hesketh et al., The Oral Neurokinin-1 Antagonist Aprepitant for the Pr

May 1, 2025EXHIBITPETITIONER

G.S. Paulekuhn et al., Trends in active pharmaceutical ingredient salt sele

May 1, 2025EXHIBITPETITIONER

S. Poli-Bigelli et al., Addition of the neurokinin 1 receptor antagonist ap

May 1, 2025EXHIBITPETITIONER

T. Qiu et al., Antiemetic regimen with aprepitant in the prevention of chem

May 1, 2025EXHIBITPETITIONER

C. Rojas, The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits su

May 1, 2025EXHIBITPETITIONER

C. Ruhlmann & J. Herrstedt, Casopitant: a novel NK1-receptor antagonist in

May 1, 2025EXHIBITPETITIONER

R. Saito et al., Roles of substance P and NK1 receptor in the brainstem in

May 1, 2025EXHIBITPETITIONER

Ronald D. Schoenwald, Pharmacokinetics in Drug Discovery and Development (2

May 1, 2025EXHIBITPETITIONER

A.G. Thomas, Netupitant and palonosetron trigger NK1 receptor internalizati

May 1, 2025EXHIBITPETITIONER

K.E. Thummel, Gut instincts: CYP3A4 and intestinal drug metabolism, 117(11)

May 1, 2025EXHIBITPETITIONER

D.S. Wang, Effect of aprepitant for the prevention of chemotherapy-induced

May 1, 2025EXHIBITPETITIONER

W. Yeo et al., A randomized study of aprepitant, ondansetron and dexamethas

May 1, 2025EXHIBITPETITIONER

S.F. Zhou, Drugs Behave as Substrates, Inhibitors and Inducers of Human Cyt

May 1, 2025EXHIBITPETITIONER

Parenteral, Merriam-Webster, https://www.merriam-webster.com/dictionary/par

May 1, 2025EXHIBITPETITIONER

NK1 receptor antagonist by Roche, Advances in Drug Discovery (Feb. 23, 2006

May 1, 2025EXHIBITPETITIONER

RxList, ALOXI (palonosetron HCl) Capsules, https://web.archive.org/web/2008

May 1, 2025EXHIBITPETITIONER

DailyMed excerpts relating to ALOXI (palonosetron HCl) Capsules, downloaded

May 1, 2025EXHIBITPETITIONER

DailyMed excerpts relating to Aloxi (palonosetron HCl) Capsules, as archive

May 1, 2025EXHIBITPETITIONER

PCT Publication WO 2011/061622, filed 18 November 2010

May 1, 2025EXHIBITPETITIONER

Provisional Patent Appl. 61/382,709, filed 14 September 2010

May 1, 2025EXHIBITPETITIONER

Provisional Patent Appl. 61/262,470, filed 18 November 2009

May 1, 2025EXHIBITPETITIONER

Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/

May 1, 2025EXHIBITPETITIONER

P. Li & L. Zhao, Developing Early Formulations: Practice and Perspective, 3

May 1, 2025EXHIBITPETITIONER

G. Sanso, Double capsule for the administration of active principles in mul

May 1, 2025EXHIBITPETITIONER

B. Cromie, Drug Combinations, 1(2) Current Medical Research and Opinion 78

May 1, 2025EXHIBITPETITIONER

Notice: Power of Attorney

May 1, 2025PAPERPETITIONER

Expert Declaration of Dr. Stephen J. Peroutka

May 1, 2025EXHIBITPETITIONER

Petition: as filed

May 1, 2025PAPERPETITIONER

SIGNED Statement - Trento'357 Petitions

May 1, 2025PAPERPETITIONER